105 related articles for article (PubMed ID: 9491793)
1. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length.
Lothstein L; Rodrigues PJ; Sweatman TW; Israel M
Anticancer Drugs; 1998 Jan; 9(1):58-66. PubMed ID: 9491793
[TBL] [Abstract][Full Text] [Related]
2. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
Lothstein L; Hosey LM; Sweatman TW; Koseki Y; Dockter M; Priebe W
Oncol Res; 1993; 5(6-7):229-34. PubMed ID: 7907237
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.
Han G; Israel M; Seshadri R; Dalton JT; Sweatman TW
Cancer Chemother Pharmacol; 1996; 37(5):472-8. PubMed ID: 8599871
[TBL] [Abstract][Full Text] [Related]
4. Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation.
Lothstein L; Sweatman TW; Dockter ME; Israel M
Cancer Res; 1992 Jun; 52(12):3409-17. PubMed ID: 1350753
[TBL] [Abstract][Full Text] [Related]
5. N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells.
Lothstein L; Wright HM; Sweatman TW; Israel M
Oncol Res; 1992; 4(8-9):341-7. PubMed ID: 1362503
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of N-benzyladriamycin-14-valerate in the rat.
Sweatman TW; Seshadri R; Israel M
Cancer Chemother Pharmacol; 1999; 43(5):419-26. PubMed ID: 10100599
[TBL] [Abstract][Full Text] [Related]
7. Comparative uptake and retention of adriamycin and N-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures.
Israel M; Sweatman TW; Seshadri R; Koseki Y
Cancer Chemother Pharmacol; 1989; 25(3):177-83. PubMed ID: 2598408
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity.
Roaten JB; Kazanietz MG; Caloca MJ; Bertics PJ; Lothstein L; Parrill AL; Israel M; Sweatman TW
Mol Cancer Ther; 2002 May; 1(7):483-92. PubMed ID: 12479266
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198).
Lothstein L; Koseki Y; Sweatman TW
Anticancer Drugs; 1994 Dec; 5(6):623-33. PubMed ID: 7888699
[TBL] [Abstract][Full Text] [Related]
10. Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta.
Roaten JB; Kazanietz MG; Sweatman TW; Lothstein L; Israel M; Parrill AL
J Med Chem; 2001 Mar; 44(7):1028-34. PubMed ID: 11297449
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
[TBL] [Abstract][Full Text] [Related]
12. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288).
Lothstein L; Suttle DP; Roaten JB; Koseki Y; Israel M; Sweatman TW
Biochem Pharmacol; 2000 Dec; 60(11):1621-8. PubMed ID: 11077044
[TBL] [Abstract][Full Text] [Related]
13. Effects of new N-alkyl analogues of adriamycin on in vitro survival and cell cycle progression of L1210 cells.
Traganos F; Israel M; Silber R; Seshadri R; Kirschenbaum S; Potmesil M
Cancer Res; 1985 Dec; 45(12 Pt 1):6273-9. PubMed ID: 4063977
[TBL] [Abstract][Full Text] [Related]
14. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
Pawlik CA; Israel M; Sweatman TW; Lothstein L
Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
[TBL] [Abstract][Full Text] [Related]
15. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
16. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic studies on N-benzyladriamycin-14-valerate (AD 198), a highly lipophilic alkyl adriamycin analog.
Lameh J; Chuang LF; Israel M; Chuang RY
Anticancer Res; 1988; 8(4):689-93. PubMed ID: 3052250
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline-induced DNA breaks and resealing in doxorubicin-resistant murine leukemic P388 cells.
Maniar N; Krishan A; Israel M; Samy TS
Biochem Pharmacol; 1988 May; 37(9):1763-72. PubMed ID: 2837239
[TBL] [Abstract][Full Text] [Related]
19. N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation.
Hofmann PA; Israel M; Koseki Y; Laskin J; Gray J; Janik A; Sweatman TW; Lothstein L
J Pharmacol Exp Ther; 2007 Nov; 323(2):658-64. PubMed ID: 17693586
[TBL] [Abstract][Full Text] [Related]
20. Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
De Graff WG; Myers LS; Mitchell JB; Hahn SM
Int J Oncol; 2003 Jul; 23(1):159-63. PubMed ID: 12792789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
